Newsletter registration

Австрия
Мост к новым рынкам

Pfizer acquisition of Baxter vaccines is concluded

Pfizer‘s acquisition of Baxter’s authorized vaccines took place at the end of 2014, with Pfizer investing a total of USD 635 million (EUR 473 million). The Baxter production site in Orth an der Donau, which currently employs a workforce of 230 people to produce a vaccine against meningococcal C and FSME, was also part of the acquisition. The integration of the product portfolio purchased from Baxter International Inc. in December 2014 has now been concluded. Since May 1, 2015, Pfizer Austria has been the marketing authorization holder of the vaccines NeisVac-C(R) and FSME-IMMUN(R).

"With the plant in Austria, we have a clear commitment to the business location Austria“, says Robin Rumler, Managing Director of Pfizer Austria. As the marketing authorization holder, Pfizer is now in possession of complete responsibility for all authorization obligations, including activities in connection with pharmacovigilance, order management, sales and invoicing, inquiries on medical data and product complaints relating to the meningococcal C and FSME vaccines. 

Share on Facebook Share on Facebook Share on Twitter Share on Twitter

Отзывы

Мероприятия

Познакомьтесь с нами в рамках мероприятий, семинаров и выставок по всему миру

Austria Map

Find the perfect location for your company

Австрия занимает ключевую позицию для бизнеса между Востоком и Западом. Мы высоко ценим превосходную инфраструктуру, в особенной мере отличное воздушное сообщение, высококвалифицированные трудовые кадры, а также первоклассное качество жизни в Вене.

ЛУКОЙЛ

Lukoil Logo
Все отзывы

Новости Австрии, как площадки для бизнеса

ABA achieves new all-time high with 344 international business location projects

Germany once again number one followed by Italy, Switzerland and Slovenia – Higher volume of investments and new jobs.

Testing the potential early detection of ovarian cancer

About 75 percent of the cases of extremely aggressive ovarian cancer (ovarian carcinoma) originally arise in the fallopian tube. Currently there are no possibilities to detect this at an early stage. A new catheter system developed by Viennese scientists could represent a new possibility to deal with this.

Все новости